Abiomed reveals positive results from PROTECT III Clinical study of Impella
PROTECT III results showed reduction in the primary endpoint of death, stroke, myocardial infarction and repeat procedures
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
27 Sep 19
PROTECT III results showed reduction in the primary endpoint of death, stroke, myocardial infarction and repeat procedures
26 Sep 19
OrbusNeich's patented immobilized antibody promotes the capture of EPCs circulating in the blood to the device surface
26 Sep 19
Interim study results from systolic heart failure patients treated with percutaneous therapy designed to improve left ventricular function…
26 Sep 19
Emergent would develop an auto-injector device, and conduct studies to validate consistency in manufacturing, functionality, and usability of…
26 Sep 19
The Impella 5.5 with SmartAssist will be introduced in the United States through a controlled rollout at hospitals…
26 Sep 19
Abbott's Architect Stat High Sensitivity Troponin-I blood test can measure very low levels of troponin
26 Sep 19
The company is collaborating with medical device and pharmaceutical firms to create combinations of therapies and data to…
25 Sep 19
Healionics’ STARgraft vascular graft is designed to resist the problems of occlusion and infection suffered by current devices
25 Sep 19
Attune Medical’s ensoETM is a single use thermal regulating device that is placed in the esophagus and connected…
24 Sep 19
FEops HEARTguide is a procedure planning environment for structural heart interventions offering physicians insights to evaluate device sizing…